Tag - MNPR

Developments

Monopar Therapeutics gets new patents for Validive

Monopar Therapeutics (NASDAQ:MNPR) received additional patents for its Phase 2b/3 clinical-stage candidate, Validive. Monopar is developing Validive for the prevention of chemoradiation-induced severe oral mucositis in...

November 9, 2020

Feature

Monopar Therapeutics readies two key clinical trials in fourth quarter

Monopar Therapeutics (NASDAQ:MNPR), which focuses on developing cancer therapies and treatments for cancer-related adverse events, is on track for two important clinical trials with its lead drug candidates, Validive...

October 6, 2020

Markets

Maxim starts Monopar Therapeutics at buy; PT $11

Maxim Group launched coverage of Monopar Therapeutics (NASDAQ:MNPR) with a “buy” rating and a 12-month price target of $11. The stock closed at $4.98 on Sept. 24. Monopar is focused on developing therapies for cancer...

September 24, 2020

Tag - MNPR

Monopar Therapeutics gets new patents for Validive

Monopar Therapeutics readies two key clinical trials in fourth quarter

Maxim starts Monopar Therapeutics at buy; PT $11

General

More